KALA BIO stock targets telehealth expansion with a USD 15.00 million LOI
Published on 09/30/2026 at 21:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
KALA BIO stock is tied to a proposed USD 15.00 million telehealth acquisition announced September 29, 2026, according to StockTitan. The transaction would add a revenue-generating healthcare platform to the biotechnology company's existing AI and ophthalmology strategy.
Telehealth deal adds revenue
The target reported USD 12.70 million in unaudited revenue for the trailing twelve months ended August 2026. It also generated over USD 48.00 million in sales since its founding in 2023 and served over 90,000 clients, according to the September 29 release carried by StockTitan.
The proposed purchase covers 100 percent of a privately held management services organization supporting a provider-led platform in all 50 states. Its business includes weight management, hormone health, longevity and sexual wellness services, with the purchase price payable through a combination of cash and KALA stock.
Due diligence sets the next test
KALA BIO has set a 45-day due diligence period expected to conclude in November 2026. The company is targeting definitive agreements and a closing in late 2026 or early 2027, subject to an audit, approvals and negotiated transaction documents.
The structure creates a clear comparison for investors: the proposed USD 15.00 million purchase price equals 1.18 times the target's USD 12.70 million trailing revenue. That ratio is based on unaudited figures supplied by target management, so the transaction's operating value depends on diligence and the final cash-stock mix.
Nasdaq quote reflects high risk
KALA BIO last traded at USD 0.43 on Nasdaq on September 30, 2026, at 3:53 p.m. ET. Its market capitalization was USD 8.2 million at that time, while the 52-week range stood at USD 0.40 to USD 95.50.
KALA BIO stock facts
- Company: KALA BIO, Inc.
- Ticker: KALA
- Primary exchange: Nasdaq
- Market capitalization: USD 8.2 million (as of September 30, 2026)
- 52-week range: USD 0.40-95.50 (as of September 30, 2026)
- Sector / Industry: Healthcare / Biotechnology
